Manuel López-Figueroa

Manuel López-Figueroa, PhD is the Chief Operating Officer (COO) at IMIDomics, Dr. Lopez-Figueroa is part of the Executive team and tasked with overseeing the day-to-day administrative and operational functions of IMIDomics.

In addition, Dr. López-Figueroa is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience and genetics from Stanford University, University of Michigan, Cornell University, HudsonAlpha Institute of Biotech, and the University of California at Irvine.

Dr. López-Figueroa is an Advisor for Bay City Capital. He had previously served as Managing Director for the firm since 2001. Bay City Capital is one of the world’s premier life science investment firms investing in over 100 companies and with more than $1.6 billion under management.

Entrepreneurial experience starting several innovative companies in the portfolio including BrainCells Inc., and Synchronicity Pharmaceuticals. Dr. López-Figueroa was involved in successful investments including Ion Torrent Systems, (acquired by Life Technologies), NextWave Pharmaceuticals (acquired by Pfizer) and Civitas (acquired by Acorda Therapeutics).

Dr. López-Figueroa has over 25 years of experience in the field of neuroscience, has won numerous awards during his academic research career, and has published extensively. He completed post- doctoral work at the University of Michigan and at the University of Copenhagen, Denmark. Dr. López received a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, Spain, respectively.

Dr. López-Figueroa serves on the boards of Oryzon Genomics (ORY.MC) and Orfan Biotech (a BridgeBio’s Pharma (BBIO) subsidiary). He is an investment advisor to Nina Capital.